Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 14:58:01 ON 11 MAY 2005

=> file caplus uspatful japio epfull medline biosis  embase scisearch
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.63       0.63

FILE 'CAPLUS' ENTERED AT 14:59:31 ON 11 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:59:31 ON 11 MAY 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 14:59:31 ON 11 MAY 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'EPFULL' ENTERED AT 14:59:31 ON 11 MAY 2005
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 14:59:31 ON 11 MAY 2005

FILE 'BIOSIS' ENTERED AT 14:59:31 ON 11 MAY 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:59:31 ON 11 MAY 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 14:59:31 ON 11 MAY 2005
Copyright (c) 2005 The Thomson Corporation

=> s (drug delivery) and oral?
   1 FILES SEARCHED...
L1        51373 (DRUG DELIVERY) AND ORAL?

=> s l1 and abus?
L2         1173 L1 AND ABUS?

=> s l2 and avers?
L3           34 L2 AND AVERS?

=> s l3 and taste
L4            9 L3 AND TASTE

=> s l4 and bitter?
L5            2 L4 AND BITTER?

=> d l5 1-2 ibib abs

L5   ANSWER 1 OF 2  USPATFULL on STN
ACCESSION NUMBER:         2005:112226  USPATFULL
TITLE:                    Compositions and methods for treatment of nervous
                          system disorders
INVENTOR(S):              Suffin, Stephen C., Sherman Oaks, CA, UNITED STATES
                          Emory, W. Hamlin, Malibu, CA, UNITED STATES
                          Brandt, Leonard, San Juan Capistrano, CA, UNITED STATES
PATENT ASSIGNEE(S):       CNS Response, Santa Anna, CA, UNITED STATES (U.S.
                          corporation)

                               NUMBER         KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 2005096311      A1   20050505
```

APPLICATION INFO.: US 2003-697497 A1 20031030 (10)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Peter G. Carroll, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105, US
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 5022

AB The present invention contemplates compositions and methods to treat patients having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Also described is a method to predict the probability of a significant recovery when a treating an individual patient having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Specifically, methods for predicting patient prognosis include, but are not limited to, quantitative electroencephalography, psychometric test batteries, biological indicators, brain metabolic indicators, genotype profiles, neuroimaging, objective test measurements and multi-modalities. The present invention also discloses a device providing an organized dispensation of the above formulations such that the patient or medical personnel may easily and accurately decrease the daily dosage of a third drug and increase the daily dosage of a formulation comprising an anticonvulsant and a neuroactive modulator.

L5 ANSWER 2 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2003:307936 USPATFULL
TITLE: Methods of using alpha 1b-adrenergic receptors
INVENTOR(S): Cotecchia, Susanna, Lausanne, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003217372	A1	20031120
APPLICATION INFO.:	US 2003-396952	A1	20030325 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-367833P	20020325 (60)
	US 2002-394423P	20020708 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ivor R. Elrifi, Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 1917
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to α-1b-adrenergic receptors and to methods for use of α1b-ARs. In particular, the invention relates to the use of such methods for the identification of modulators of α1b-adrenergic receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l4 1-9 ibib abs

L4 ANSWER 1 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:112226 USPATFULL
TITLE: Compositions and methods for treatment of nervous

system disorders

INVENTOR(S): Suffin, Stephen C., Sherman Oaks, CA, UNITED STATES
Emory, W. Hamlin, Malibu, CA, UNITED STATES
Brandt, Leonard, San Juan Capistrano, CA, UNITED STATES

PATENT ASSIGNEE(S): CNS Response, Santa Anna, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005096311	A1	20050505	
APPLICATION INFO.:	US 2003-697497	A1	20031030	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Peter G. Carroll, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105, US
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 5022

AB The present invention contemplates compositions and methods to treat patients having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Also described is a method to predict the probability of a significant recovery when a treating an individual patient having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Specifically, methods for predicting patient prognosis include, but are not limited to, quantitative electroencephalography, psychometric test batteries, biological indicators, brain metabolic indicators, genotype profiles, neuroimaging, objective test measurements and multi-modalities. The present invention also discloses a device providing an organized dispensation of the above formulations such that the patient or medical personnel may easily and accurately decrease the daily dosage of a third drug and increase the daily dosage of a formulation comprising an anticonvulsant and a neuroactive modulator.

L4 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:63688 USPATFULL
TITLE: Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha

INVENTOR(S): Fu, Jin, Irvine, CA, UNITED STATES
Gaetani, Silvana, Irvine, CA, UNITED STATES
Piomelli, Daniele, Irvine, CA, UNITED STATES

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005054730	A1	20050310	
APPLICATION INFO.:	US 2004-884617	A1	20040701	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-112509, filed on 27 Mar 2002, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-485062P	20030702	(60)
	US 2001-336289P	20011031	(60)
	US 2001-279542P	20010327	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 53

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 3832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compounds, compositions, and methods for the treatment of disorders and conditions mediated by PPARα. The invention relates to the surprising discovery that oleoylethanolamide (OEA) is an endogenous high affinity and selective ligand of PPARα. The compounds of the invention include, but are not limited to, specific PPARα agonists sharing the receptor binding properties of OEA and fatty acid alkanolamides and their homologs which also are PPARα agonists. Such OEA-like compounds include, but are not limited to, compounds of the following formula: ##STR1##

in which n is from 0 to 5, the sum of a and b can be from 0 to 4; Z is a member selected from the group consisting of --C(O)N(R.sup.o)--; --(R.sup.o)NC(O)--; --OC(O)--; --(O)CO--; O; NR.sup.o; and S; and wherein R.sup.o and R.sup.2 are members independently selected from the group consisting of unsubstituted or unsubstituted alkyl, hydrogen, C.sub.1-C.sub.6 alkyl, and lower (C.sub.1-C.sub.6) acyl, and wherein up to eight hydrogen atoms are optionally substituted by methyl or a double bond, and the bond between carbons c and d may be unsaturated or saturated, or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:24092 USPATFULL
TITLE: Therapeutic and diagnostic methods dependent on CYP2A enzymes
INVENTOR(S): Sellers, Edward Moncrieff, Toronto, CANADA
Tyndale, Rachel F., Toronto, CANADA
PATENT ASSIGNEE(S): Nicogen, Inc., St. Lurent, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005020641	A1	20050127
APPLICATION INFO.:	US 2004-815995	A1	20040402 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-584669, filed on 1 Jun 2000, PENDING Continuation of Ser. No. WO 1998-CA10193, filed on 1 Dec 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67020P	19971201 (60)
	US 1997-67021P	19971201 (60)
	US 1998-84847P	19980508 (60)
	US 1998-107392P	19981106 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUNTON & WILLIAMS LLP, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 2539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease the production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic

(i.e., prevention and treatment) compositions and methods are also described, including an improved **oral** nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme. Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as "CYP2A6" for brevity) is predictive of an individual who: (1) has a decreased risk of becoming a smoker, (ii) will smoke less if he/she becomes dependent, and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6-mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analyzing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:307936 USPATFULL
TITLE: Methods of using alpha 1b-adrenergic receptors
INVENTOR(S): Cotecchia, Susanna, Lausanne, SWITZERLAND

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003217372	A1	20031120	
APPLICATION INFO.:	US 2003-396952	A1	20030325	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-367833P	20020325 (60)
	US 2002-394423P	20020708 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ivor R. Elrifi, Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 1917
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to α-1b-adrenergic receptors and to methods for use of α1b-ARs. In particular, the invention relates to the use of such methods for the identification of modulators of α1b-adrenergic receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:166617 USPATFULL
TITLE: Methods for the treatment of addiction
INVENTOR(S): Fox, Barbara S., Wayland, MA, UNITED STATES
Jorgenson D'Orlando, Kay, Wayland, MA, UNITED STATES
PATENT ASSIGNEE(S): Addiction Therapies, Inc., Wayland, MA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003114475	A1	20030619	
APPLICATION INFO.:	US 2002-285038	A1	20021031	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-334706P	20011031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to addiction treatment methods that include frequent or episodic dosing of medication coupled with a reinforcing behavior and/or stimulus. Performing a particular behavior and/or experiencing a particular stimulus in conjunction with administering medication causes patients to become engaged in therapy and focus on recovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 9 USPATFULL on STN
ACCESSION NUMBER: 92:20816 USPATFULL
TITLE: Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
INVENTOR(S): Sinclair, John D., Espoo, Finland
PATENT ASSIGNEE(S): Alko Ltd., Helsinki, Finland (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5096715		19920317	
APPLICATION INFO.:	US 1989-439050		19891120	(7)

DISCLAIMER DATE: 20061121
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Spear, James M.
LEGAL REPRESENTATIVE: Armstrong, Nikaido, Marmelstein, Kubovcik & Murray
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 471
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating alcoholism by extinguishing the alcohol-drinking response in which an opiate antagonist is transdermally administered to a subject and a device for transdermally administering the antagonist. The device is a package containing a fixed dose of opiate antagonist, a vehicle and a permeation enhancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 9 USPATFULL on STN
ACCESSION NUMBER: 89:94175 USPATFULL
TITLE: Method for treating alcohol-drinking response
INVENTOR(S): Sinclair, John D., Espoo, Finland
PATENT ASSIGNEE(S): Alko Limited, Helsinki, Finland (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4882335		19891121	
APPLICATION INFO.:	US 1988-205758		19880613	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Friedman, Stanley J.

LEGAL REPRESENTATIVE: Armstrong, Nikaido, Marmelstein, Kubovcik & Murray
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 381
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A therapeutic method is provided for use as an adjunct in the treatment of alcoholism. The method consists of extinguishing the alcohol-drinking response of alcoholics during a relatively short period of time by having them drink alcoholic beverage repeatedly while an opiate antagonist blocks the positive reinforcement effects of ethanol in the brain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 9 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1990:21452 EPFULL
DATA UPDATE DATE: 19950308
DATA UPDATE WEEK: 199510
TITLE (ENGLISH): Use of an opiate antagonist for the preparation of a pharmaceutical composition to be transdermally administered, and device for transdermal delivery
TITLE (FRENCH): Utilisation d'un antagoniste d'opiates pour la preparation d'une composition pharmaceutique a administration transdermique et dispositif pour la delivrance percutanee
TITLE (GERMAN): Verwendung eines Opiatantagonisten zur Herstellung eines transdermal zu verabreichenden Arzneimittels sowie eine Vorrichtung zur transdermalen Verabreichung
INVENTOR(S): Sinclair, John David, Nokkalanniemi 7, F-02230 Espoo, FR
PATENT APPLICANT(S): Alko Ltd., P.O. Box 350, 00101 Helsinki, FI
PATENT APPL. NUMBER: 854720
AGENT: VOSSIUS & PARTNER, Postfach 86 07 67, 81634 Muenchen, DE
AGENT NUMBER: 100311
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPB1 Granted patent
PATENT INFORMATION:

NUMBER	KIND	DATE
EP 429039	B1	19950308

DESIGNATED STATES: AT BE CH DE DK ES FR GB GR IT LI LU NL SE
APPLICATION INFO.: EP 1990-122076 A 19901119
PRIORITY INFO.: US 1989-439050 A 19891120
CITED PATENT LIT.:

EP 19423	A
EP 171742	A
EP 346830	A
WO 8400889	A
DE 3545926	A
GB 2174605	A
US 2837881	A
US 4351337	A

L4 ANSWER 9 OF 9 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1989:10346 EPFULL
DATA UPDATE DATE: 19980225

DATA UPDATE WEEK:	199809
TITLE (ENGLISH):	Use of opiate antagonists for the preparation of a pharmaceutical composition for the treatment of alcoholism
TITLE (FRENCH):	Utilisation des antagonistes des opiates pour obtenir une composition pharmaceutique de traitement de l'alcoolisme
TITLE (GERMAN):	Verwendung von Opium-Antagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Alkoholismus
INVENTOR(S):	Sinclair, John David, Nokkalaniemi 7, SF-02230 Espoo, FI
PATENT APPLICANT(S):	ALKO LIMITED, Salmisaarenranta 9 P.O. Box 305, 00101 Helsinki, FI
PATENT APPL. NUMBER:	854722
AGENT:	VOSSIUS & PARTNER, Postfach 86 07 67, 81634 Muenchen, DE
AGENT NUMBER:	100311
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
LANGUAGE OF PROCEDURE:	English
LANGUAGE OF TITLE:	German; English; French
DOCUMENT TYPE:	Patent
PATENT INFO TYPE:	EPB1 Granted patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
EP 346830	B1	19950510

DESIGNATED STATES:	AT BE CH DE ES FR GB GR IT LI LU NL SE
APPLICATION INFO.:	EP 1989-110688 A 19890613
PRIORITY INFO.:	US 1988-205758 A 19880613

CITED NON PATENT LIT.:

NIDA Research Monographs 28 (1980),11 - 22;

Arch. Gen. Psychiatry 49 (1992), 881 - 887;

Opioids, Bulimia, and Alcohol Abuse & Alcoholism, Springer Verlag (1990), 195 - 214;

Novel Pharmacological Interventions for Alcoholism, Springer Verlag (1992), 149 - 157;

Ann. Med. 22 (1990), 357 - 362;

Alcoholism: Clinical and Experimental Research (1993), 1 - 10;

Pharmacology Biochemistry and Behavior (1993), 1 - 9;

Arch. Gen. Psychiatry 49 (1992), 876;

PHARMACOLOGY, BIOCHEMISTRY & BEHAVIOR, Vol. 22, no.1 Jan. 1985, pages 91-99, US; H.H. SAMSON et al.;

BRITISH JOURNAL OF ADDICTION, vol. 82, no. 11, Nov. 1987, pages 1213-1223, GB; J.D. SINCLAIR et al;

PHARMACOLOGY, BIOCHEMISTRY & BEHAVIOR, vol. 18. suppl 1, 1983, pages 537-539, Ankho International, US; P. Marfaing-JALLAT et al.;

NATURE, vol. 265, 6th Jan. 1977, pages49-51, GB; K. BLUM et al.;

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR, vol. 19, no. 6, Dec. 1983, pages 1045-1048, Ankho International Inc., US; J.D.SINDEN et al.;

LIFE SCIENCES, vol. 26, no.9, 3nd March 1980, pages 679-688, PERGAMON PRESS LTD, US; H.L. ALTSHULER ET AL.;

ALCOHOL AND ALCOHOLISM, vol. 22, no. 2 1987, pages 117-119, GB; J. KOTLINSKA et al.;

ALCOHOL, vol. 3, no. 6, Nov/Dec. 1986, pages 383-388 US; R.D. MYERSet al.;

LA CLINICA TERAPEUTICA, vol, 127. no. 3, 1988, pages 173-180, IT; F. CUGURRA;

THE INTERNATIONAL JOURNAL OF THE ADDICTIONS, vol. 20, no. 6/7, 1985, pages 947-969, Marcel Dekker, Inc. US, A.R. CHILDRESS et al.;
NIDA RESEARCH MONOGRAPH 28, 1981 US; P.F. RENAULT

CITED PATENT LIT.: EP 19423 A
US 3966940 A
US 5086058 A

=> d his

(FILE 'HOME' ENTERED AT 14:58:01 ON 11 MAY 2005)

FILE 'CAPLUS, USPATFULL, JAPIO, EPFULL, MEDLINE, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 14:59:31 ON 11 MAY 2005

L1 51373 S (DRUG DELIVERY) AND ORAL?
L2 1173 S L1 AND ABUS?
L3 34 S L2 AND AVERS?
L4 9 S L3 AND TASTE
L5 2 S L4 AND BITTER?

=> s l3 and (aversive agent#)
L6 12 L3 AND (AVERSIVE AGENT#)

=> d l6 1-12 ibib abs

L6 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:533655 CAPLUS
DOCUMENT NUMBER: 141:76780
TITLE: Pharmaceutical formulation including a resinate and a narcotic **aversive agent**
INVENTOR(S): Hughes, Lyn; Bellamy, Simon Andrew
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 16,336.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004126428	A1	20040701	US 2003-713926		20031114
US 2003068276	A1	20030410	US 2001-16336		20011102
PRIORITY APPLN. INFO.:			US 2001-16336	A2	20011102
			US 2001-322624P	P	20010917

AB The present invention provides a pharmaceutical that includes, in combination, a core, and a coating surrounding the core comprising a resinate of an opiate. The pharmaceutical **oral** dosage form is failsafe, and not subject to **abuse**. A composition was prepared containing a complex of oxycodone/bitrex/ion exchanger with sulfonic acid functionality in the Na form.

L6 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:219662 CAPLUS
DOCUMENT NUMBER: 138:243304
TITLE: **Oral** pharmaceutical dosage forms with reduced potential for drug **abuse**, comprising respiratory irritants or bitter substances
INVENTOR(S): Hugues, Lyn; Bellamy, Simon Andrew
PATENT ASSIGNEE(S): Rohm and Haas Company, USA
SOURCE: Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 1293195	A1	20030319	EP 2002-256157		20020905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
US 2003068276	A1	20030410	US 2001-16336		20011102
JP 2003113074	A2	20030418	JP 2002-269709		20020917
PRIORITY APPLN. INFO.:			US 2001-322624P	P	20010917
			US 2001-16336	A	20011102

AB Solid **oral** dosage forms of controlled substances containing **aversive agents** are useful in reducing **abuse** by chewing or inhaling. Extended release oxycodone tablets contained oxycodone.HCl 30, lactose 200, Eudragit RS PM 45, purified water as needed, stearyl alc. 75, talc 7.5, magnesium stearate 3.75, capsaicin 13.75 mg/tablet.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:154160 CAPLUS
DOCUMENT NUMBER: 138:210297
TITLE: Pharmaceutical formulations containing dye
INVENTOR(S): Gruber, Thomas
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003015531	A2	20030227	WO 2002-US24549		20020801
WO 2003015531	A3	20031106			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005089475	A1	20050428	US 2004-772647		20040204
PRIORITY APPLN. INFO.:			US 2001-310513P	P	20010806
			WO 2002-US24549	A1	20020801

AB Methods and compns. for preventing **abuse** of dosage forms comprising an opioid analgesic and an **aversive agent** (e.g., a dye) in an effective amount to deter an **abuser** from administering a tampered form of the dosage form i.v., intranasally, and/or **orally** are revealed. Formulation of a tablet containing 20 mg oxycodone hydrochloride and 1.2 mg FD & C Blue Number 2 is disclosed.

L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:132999 CAPLUS

DOCUMENT NUMBER: 138:175867
TITLE: Compositions containing bitter agents to prevent **abuse** of opioids
INVENTOR(S): Breder, Christopher; Colucci, Robert; Oshlack, Benjamin; Sackler, Richard; Wright, Curtis
PATENT ASSIGNEE(S): Euro-Celtique S.A., Luxembourg
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013479	A1	20030220	WO 2002-US24934	20020806
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2456322	AA	20030220	CA 2002-2456322	20020806
US 2003068392	A1	20030410	US 2002-214409	20020806
US 2003068371	A1	20030410	US 2002-214413	20020806
US 2003124185	A1	20030703	US 2002-213921	20020806
EP 1414418	A1	20040506	EP 2002-750438	20020806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
DE 20220910	U1	20040909	DE 2002-20220910	20020806
JP 2005501067	T2	20050113	JP 2003-518489	20020806
PRIORITY APPLN. INFO.:			US 2001-310515P P	20010806
			US 2001-310516P P	20010806
			US 2001-310537P P	20010806
			WO 2002-US24934 W	20020806

AB Methods and compns. for preventing **abuse** of dosage forms of an opioid analgesic and an opioid antagonist including at least 1 **aversive agent** in an effective amount to deter an **abuser** from administering a tampered form of the dosage form i.v., intranasally, and/or **orally**. Thus, a formulation contained oxycodone-HCl 20.0, spray-dried lactose 59.25, Povidone 5.0, Eudragit RS30D 10.0, triacetin 2.0, naloxone-HCl 0.61, denatonium benzoate 0.07, stearyl alc. 25.0, talc 2.5, Mg stearate 1.25, and Opadry Pink YS14518A 5.0 mg/ unit.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:132997 CAPLUS
DOCUMENT NUMBER: 138:175865
TITLE: Compositions containing bitter agents to prevent **abuse** of opioids
INVENTOR(S): Breder, Christopher; Colucci, Robert; Oshlack, Benjamin; Sackler, Richard; Wright, Curtis
PATENT ASSIGNEE(S): Euro-Celtique S.A., Luxembourg
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013476	A1	20030220	WO 2002-US24935	20020806
WO 2003013476	B1	20030703		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2455420	AA	20030220	CA 2002-2455420	20020806
US 2003064099	A1	20030403	US 2002-213920	20020806
US 2003068370	A1	20030410	US 2002-214410	20020806
US 2003068375	A1	20030410	US 2002-214412	20020806
EP 1414413	A1	20040506	EP 2002-752708	20020806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
DE 20220917	U1	20040923	DE 2002-20220917	20020806
JP 2005500364	T2	20050106	JP 2003-518486	20020806

PRIORITY APPLN. INFO.:

US 2001-310514P	P	20010806
US 2001-310534P	P	20010806
US 2001-310535P	P	20010806
WO 2002-US24935	W	20020806

AB Methods and compns. for preventing **abuse** of dosage forms comprise an opioid analgesic or other drug which may be the subject of **abuse**, and at least one **aversive agent** in an effective amount to deter an **abuser** from administering a tampered form of the dosage form i.v., intranasally, and/or **orally**. Thus, a formulation contained oxycodone-HCl 20.0, spray-dried lactose 59.25, Povidone 5.0, Eudragit RS30D 10.0, triacetin 2.0, xanthan gum 9.0, stearyl alc.25.0, talc 2.5, Mg stearate 1.25, and Opadry Pink YS-14518A 5.0 mg/unit.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2001:103006 USPATFULL
TITLE: Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol **abuse**
INVENTOR(S): Vallee, Bert L., Brookline, MA, United States
Keung, Wing-Ming, Wayland, MA, United States
PATENT ASSIGNEE(S): The Endowment for Research in Human Biology, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6255497	B1	20010703
APPLICATION INFO.:	US 1998-190360		19981112 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-840360, filed on 29 Apr 1997, now patented, Pat. No. US 5886028 Continuation of Ser. No. US 170272, now patented, Pat. No. US 5624910
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Solola, Taofiq A.

LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2163
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compounds for inhibiting aldehyde dehydrogenase are disclosed. The compounds are useful as pharmaceutical compositions in methods for therapeutically treating alcohol consumption in a human.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2000:124585 USPATFULL
TITLE: **Oral** formulations for controlled release of alcohol deterrents
INVENTOR(S): Whitmire, David R., P.O. Box 393, Watkinsville, GA, United States 30677-0393

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6120806		20000919	
APPLICATION INFO.:	US 1997-882176		19970625	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Webman, Edward J.
LEGAL REPRESENTATIVE: Arnall Golden & Gregory, LLP
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 881
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An **oral** controlled release dosage form for cyanamide whereby a portion of a cyanamide dose administered to a patient remains transiently partitioned within encapsulating material, thereby retarding metabolism of the total administered cyanamide dose, is described. No investigator has reported the use of dosage forms enabling controlled release of cyanamide. The preparation, when administered to ethanol metabolizing individuals, can elevate blood acetaldehyde to such levels, and for such periods of time, that the individuals will be deterred from future alcohol consumption. The controlled release of cyanamide provides an optimal time-profile of alcohol deterrence specific for individual patients. The formulation avoids the side-effects associated with the relatively high concentrations of cyanamide and cyanamide-metabolites, and the attendant untoward toxic effects, caused by a typical bolus cyanamide dose, thereby attenuating the intensity of the sickness caused by acetaldehyde, and increasing patient compliance with cyanamide therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 12 USPATFULL on STN
ACCESSION NUMBER: 1999:163703 USPATFULL
TITLE: Bromocriptine for the treatment of alcoholics diagnosed with the D.sub.2 dopamine receptor DRD2 A1 allele
INVENTOR(S): Noble, Ernest P., South Laguna, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6001848		19991214	
APPLICATION INFO.:	US 1997-822659		19970324	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-14136P	19960325 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Moezie, M.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are dopamine agonist and opioidergic compositions and methods for their use in the treatment of alcoholism. The invention discloses compounds and therapeutic kits useful in the treatment of alcoholics having the A1 allele of the dopamine receptor D2 gene. Also disclosed are methods of treating alcoholics having the A1/A1 or A1/A2 DRD2 genotype comprising administration of dopamine agonists such as aporphines, ergolines, related compounds, and their analogs, in combination with opioidergic compounds such as naloxone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 12 USPATFULL on STN
ACCESSION NUMBER: 1999:37142 USPATFULL
TITLE: Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol **abuse**
INVENTOR(S): Vallee, Bert L., Brookline, MA, United States
Keung, Wing-Ming, Wayland, MA, United States
PATENT ASSIGNEE(S): The Endowment for Research in Human Biology, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5886028		19990323
APPLICATION INFO.:	US 1997-840360		19970429 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-170272, filed on 24 May 1994, now patented, Pat. No. US 5624910 which is a continuation-in-part of Ser. No. US 1991-723404, filed on 1 Jul 1991, now patented, Pat. No. US 5204369
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Keating, Dominic
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compounds for inhibiting aldehyde dehydrogenase are disclosed. The compounds are useful as pharmaceutical compositions in methods for therapeutically treating alcohol consumption in a human.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 12 USPATFULL on STN
ACCESSION NUMBER: 97:36170 USPATFULL
TITLE: Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol **abuse**

INVENTOR(S):	Vallee, Bert L., Brookline, MA, United States Keung, Wing-Ming, Wayland, MA, United States		
PATENT ASSIGNEE(S):	The Endowment for Research in Human Biology, Inc., Boston, MA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5624910		19970429
	WO 9300896		19930121
APPLICATION INFO.:	US 1994-170272		19940524 (8)
	WO 1992-US5598		19920630
			19940524 PCT 371 date
			19940524 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-723404, filed on 1 Jul 1991, now patented, Pat. No. US 5204369		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Nicky		
LEGAL REPRESENTATIVE:	Banner & Allegretti, Ltd.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2449		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for inhibiting aldehyde dehydrogenase activity using daidzin and/or daidzin analog and/or daidzin or daidzin analog in combination with a factor or factors which increase the bioavailability of the daidzin or daidzin analog, as ALDH-I inhibitory compounds or compositions. Such inhibitory compounds or compositions are useful as pharmaceutical compositions in methods for the treatment of alcohol dependence (i.e., alcoholism) or alcohol **abuse**, for alcohol sensitization, for extinguishing an alcohol-drinking response, for suppressing an urge for alcohol, for inducing alcohol intolerance, for preventing alcoholism in an individual with or without a susceptibility or predisposition to alcoholism or alcohol **abuse**, and for limiting alcohol consumption in an individual whether or not genetically predisposed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 12 USPATFULL on STN

ACCESSION NUMBER:	93:31436 USPATFULL		
TITLE:	Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol **abuse**		
INVENTOR(S):	Vallee, Bert L., Brookline, MA, United States Keung, Wing M., Wayland, MA, United States		
PATENT ASSIGNEE(S):	The Endowment For Research In Human Biology, Boston, MA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5204369		19930420
APPLICATION INFO.:	US 1991-723404		19910701 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Waddell, Frederick E.		
ASSISTANT EXAMINER:	Tsung, Frederick F.		
LEGAL REPRESENTATIVE:	Allegretti & Witcoff, Ltd.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	1939		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for inhibiting aldehyde dehydrogenase activity using daidzin as a selective inhibitor of ALDH-I activity. Because daidzin is a potent selective, yet reversible, inhibitor of ALDH-I activity, it is useful as a pharmaceutical composition in methods for the treatment of alcohol dependence (i.e., alcoholism) or alcohol **abuse**, for alcohol sensitization, for extinguishing an alcohol-drinking response, for suppressing an urge for alcohol, for inducing alcohol intolerance, for preventing alcoholism in an individual with or without a susceptibility or predisposition to alcoholism or alcohol **abuse**, and for limiting alcohol consumption in an individual whether or not genetically predisposed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 12 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER:	1992:53532 EPFULL
DATA UPDATE DATE:	20040922
DATA UPDATE WEEK:	200439
TITLE (ENGLISH):	METHOD FOR THE INHIBITION OF ALDH-I USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL **ABUSE**
TITLE (FRENCH):	PROCEDE D'INHIBITION DE L'ALDH-I EFFICACE DANS LE TRAITEMENT DE LA DEPENDANCE A L'ALCOOL OU DE L' **ABUS** D'ALCOOL
TITLE (GERMAN):	VERFAHREN ZUR INHIBIERUNG VON ALDH-I ZUR BEHANDLUNG VON ALKOHOLABHAENGIGKEIT ODER-MISSBRAUCH
INVENTOR(S):	VALLEE, Bert, L., 56 Browne Street, Brookline, MA 02146, US; KEUNG, Wing, Ming, 2 Juniper Lane, Wayland, MA 01778, US
PATENT APPLICANT(S):	THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC., (ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC., THE; HUMAN BIOLOGY, INC., THE ENDOWMENT FOR RESEARCH IN; BIOLOGY, INC., THE ENDOWMENT FOR RESEARCH IN HUMAN), Seeley G. Mudd Building, Room 105, 250 Longwood Avenue, Boston, MA 02115, US
PATENT APPL. NUMBER:	1603720
AGENT:	Pett, Christopher Phineas, et al, Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street, London EC4V 4EL, GB
AGENT NUMBER:	41341
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
LANGUAGE OF PROCEDURE:	English
LANGUAGE OF TITLE:	German; English; French
DOCUMENT TYPE:	Patent
PATENT INFO TYPE:	EPB1 Granted patent
PATENT INFORMATION:	
PATENT INFORMATION:	

NUMBER	KIND	DATE
NUMBER	KIND	DATE
EP 592583	B1	20010131
WO 9300896		19930121

DESIGNATED STATES:	AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
APPLICATION INFO.:	EP 1992-915216 A 19920630
	WO 1992-US5598 A 19920630
PRIORITY INFO.:	US 1991-723404 A 19910701
CITED NON PATENT LIT.:	YAKUGAKU ZASSHI vol. 109, no. 6, June 1989, JAPAN pages 424 - 431 NIIHO ET AL. 'Pharmacological studies on Puerariae flos . I The effects of Puerariae flos on

alcoholic metabolism and spontaneous mouvement in mice';
;
PATENT ABSTRACTS OF JAPAN;
CHINESE PATENTS ABSTRACTS IN ENGLISH AN:2105710;
PATENT ABSTRACTS OF JAPAN vol. 008, no. 71 3 April 1984;
CHIN. MED. J. May 1974, pages 271 - 274 FANG C.C. ET AL. 'Studies on flavones of Radix puerariae';
CHIN. MED. J. May 1974, pages 265 - 270 TSENG,K.Y. ET AL. 'Pharmacologic studies on Radix puerariae. I Effects on dog arterial pressure, vascular reactivity, cerebral and peripheral circulation';
FINN. CHEM. LETT. vol. 16, no. 1-6, 1989, pages 79 - 83 W[H[L[K. ET AL 'Monoalkylation of Daidzein (7,4'-Dihydroxyisoflavone). Synthesis of 7-O-(carboxybutyl) equol.';
YAO HSUEH HSUEH PAO vol. 15, no. 9, 1980, pages 538 - 547 SHAO G. ET AL. 'Studies on the synthesis and structure biological activity relationships of Daidzein and its derivatives.';
PATENT ABSTRACTS OF JAPAN vol. 11, no. 353 (C-457)(2800) 18 November 1987

CITED PATENT LIT.:

EP 248420	A
WO 9115483	A
DE 1210882	B